Details up front: 96.8% · retatrutide.
This should be a straightforward calculation and I keep getting two different answers.
The numbers are arbitrary; the method is what I am after.
Can someone show the working rather than just the answer?
Read the chromatogram before you read the number, because the number without the trace is not a measurement, it is a claim.
Gradient slope controls resolution, and gentler slopes resolve co-eluting impurities into separate peaks — so the better method reports the worse purity number.
| Test | Answers | Does NOT answer |
|---|---|---|
| RP-HPLC, area % | What fraction of detected material is the target | How much target is present |
| Quantified content | Milligrams of peptide per vial | What the impurities are |
| ESI-MS identity | Whether the molecular weight matches | Purity, or isomeric substitution |
| Peptide mapping | Sequence, localised to a fragment | Quantity |
| Karl Fischer | Water content of the solid | Solvent content |
| LAL endotoxin | Pyrogen load in EU/mg | Sterility |
| Sterility test | Growth in defined media over 14 days | Endotoxin, or bioburden count |
On the detail: column pore size affects mass transfer — a 100 Angstrom packing on a 5 kDa peptide restricts diffusion, broadening the peak and potentially hiding small impurities in the shoulders.
If you are ranking vendors, specify a method and have all samples tested at the same place.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsReporting threshold is convention and not chemistry, which is why two certificates with different thresholds disagree by a tenth of a point or more.
Detection wavelength matters because 214 nm sees the peptide backbone while 280 nm sees only aromatic side chains — so truncation impurities lacking a tryptophan are invisible at 280 nm.
Temperature affects the dynamics of molecular conformation, and if a peptide has proline residues that interconvert on the chromatographic timescale, the peak will split or shoulder at low temperature and collapse at high temperature.
Inter-laboratory studies on identical peptide material routinely find half-a-per-cent to a full-per-cent spreads in reported purity on the same sample.
The caveat is that purity without identity is only half an answer — a high purity does not mean the peak is actually what you think it is.
Compare purity within a single laboratory on the same method, never across laboratories.
It helps to be literal here: understanding purity requires separating the chemistry from the method from the reporting convention, and the three are not independent.
Mobile phase additive choice affects ionisation and peak shape — TFA gives sharp peaks but suppresses mass spectrometry signal, formic acid gives worse peaks but preserves signal.
Tailing factor measures peak shape, and a badly tailing peak spreads into the region where small impurities live, forcing tangent-skim integration that assigns tail area to the main peak.
The ICH Q3A impurity thresholds and the relevant pharmacopoeial chapters all specify method validation requirements that almost no research-grade certificate claims to meet.
I would be careful about over-reading a single measurement — treat it as a data point, not as ground truth.
The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.
Area percentage is not mass percentage, and conflating the two is the most common misreading of a purity figure.
Mass on column affects detector linearity and peak overlap — overloading broadens peaks and hides neighbours, while underloading improves resolution but loses sensitivity.
The limitation is that single-digit micro-impurities become invisible at typical reporting thresholds, so "no impurities detected" means "none above one in two thousand."
If you are ranking vendors, specify a method and have all samples tested at the same place.
edited 16 Jul 2024 by b_delacroix — added a caveat about sampling
Put another way, the method matters more than the vial, which is why specifying a method buys you far more than changing suppliers does.
Retention time is sequence-specific and method-specific, so comparing your result to a supplier value using a different method is meaningless without method documentation.
Published side-by-side method comparisons show that a two-point difference in purity on the same vial is easily explained by method choice alone.
Compare purity within a single laboratory on the same method, never across laboratories.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.